MiR-1299 Impedes the Progression of Non-Small-Cell Lung Cancer Through EGFR/PI3K/AKT Signaling Pathway
Authors Cao S, Li L, Li J, Zhao H
Received 18 February 2020
Accepted for publication 8 July 2020
Published 30 July 2020 Volume 2020:13 Pages 7493—7502
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Federico Perche
Shengya Cao,1,* Longfei Li,2,* Jia Li,3 Hongying Zhao4
1Department of Clinical Laboratory, Xuzhou Cancer Hospital, Xuzhou, Jiangsu, People’s Republic of China; 2Department of Thoracic Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu, People’s Republic of China; 3Department of Central Laboratory, Xuzhou Cancer Hospital, Xuzhou, Jiangsu, People’s Republic of China; 4Department of Oncology, Xuzhou Cancer Hospital, Xuzhou, Jiangsu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hongying Zhao
Department of Oncology, Xuzhou Cancer Hospital, Xuzhou, Jiangsu, People’s Republic of China
Background: Non-small-cell lung cancer (NSCLC) is one of the most malignant tumors. In which, numerous miRNAs had been reported to participate in the pathogenesis. However, the expression and function of miR-1299 in NSCLC are not clear.
Methods: To explore the roles of miR-1299 in NSCLC, we detected the levels of miR-1299 in clinical samples of NSCLC and investigated the role of miR-1299 in the regulation of the NSCLC cells proliferation, metastasis, and EMT. Luciferase reporter assay was employed to verify the target of miR-1299. Additionally, the proliferation, metastasis, and EMT of A549 and H1299 cells were analyzed after the overexpression and knockdown of miR-1299.
Results: We found that the miR-1299 expression negatively corresponded with the clinical stage and overall survival in NSCLC patients. Overexpression of miR-1299 inhibited the migration, invasion, and EMT of A549 and H1975 cells. Meanwhile, we proved that miR-1299 is the sponge of EGFR. Besides, our results suggested that miR-1299 inhibits the progression of NSCLC cells through the PI3K/Akt signal pathway.
Conclusion: We demonstrated that miR-1299 inhibits the progression of NSCLC through the EGFR/PI3K/Akt signal pathway. Therapeutic intervention targeting the miR-1299 may provide a potential strategy for the treatment of NSCLC.
Keywords: miR-1299, NSCLC, EGFR, PI3K/Akt
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]